

Godavari Biorefineries Limited

Investor Presentation | Q1 FY27

CREATING A BEAUTIFUL WORLD

*With Innovation at the Core,
Unified in Growth, Sustainability & Inclusivity.*



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Godavari Biorefineries Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale.

All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

**SAMIR SOMAIYA**

Chairman & Managing Director

**CREATING A
BEAUTIFUL
WORLD****Everything we do begins with the sun, the soil and the small farmer.**



COMMENCEMENT OF OPERATIONS

Sameerwadi Dual Feedstock Distillery

Godavari's dual-feedstock **200 KLPD** corn/grain-based distillery commences operations at Sameerwadi, Karnataka.

Alongside existing sugarcane juice operations, the facility can process corn and grain, allowing **smoother transitions** between raw materials based on seasonal availability.

The commencement marks a meaningful step forward in building a stronger, more adaptable bio-based manufacturing system.

CAPACITY IMPACT

+60M Litres

Adds 60 million litres of annual ethanol capacity, taking GBL's total to **800 KLPD**.





TOTAL INCOME

₹559.9 Cr

▲ 4.9% YoY

(₹534.0 crore in Q1 FY26)



BIO-BASED CHEMICALS

53%

EBITDA Growth YoY

11.4%

EBITDA Margin
vs 8.9% in Q1 FY26



ETHANOL

200 KLPD

Grain-based distillery
commissioned

800 KLPD

Total Capacity



DRUG DISCOVERY

Japanese Patent

Granted for Novel Anti-cancer
Molecule

CDSCO Application

Filed for Preliminary
Efficacy Trials for our Lead Novel
Anti-cancer Molecule

Bio based Chemicals



Bio-based Chemicals
EBITDA increased 53% YoY
in Q1 FY27.



EBITDA margin expansion to
11.4% Q1FY27 from 8.9% in
Q1 FY26.



Secured an Indian patent for a
cost-effective process to
manufacture branched
alcohols, strengthening the
Company's intellectual
property portfolio.



Debottlenecking initiatives
completed in FY26 are
translating into improved
earnings in FY27.

Integrated Sugar, Co-gen & Ethanol



Successfully commissioned the 200 KLPD corn/grain-based distillery, increasing total distillery capacity to 800 KLPD and enhancing dual-feedstock flexibility.



Improved sugar realizations supported revenue during Q1 FY27.



While the industry remains watchful of potential El Niño-related risks, we remain focused on improving yields.

Drug Discovery Accomplishments And Pipeline



Granted a Japanese patent for a novel anti-cancer molecule, further strengthening our global intellectual property portfolio.



Filed with CDSCO for efficacy trials for our Lead Novel Anti-cancer Molecule



Continued progress in innovation-led research to develop next-generation bio-based technologies and healthcare solutions.

Bio-Based Solutions Take Centre Stage

As fossil fuel supply chains face mounting stress, industries are turning to reliable, sustainable alternatives. GBL is positioned at the heart of this shift - from oil to soil.



GBL- The Trusted Supply Partner

- Customers are choosing dependable, integrated bio-based partners over fossil-based suppliers.
- GBL's integrated biorefinery model is precisely what the market now demands.



Bio-Based – More Acceptable

- Improved global adoption of bio-based chemicals is opening new, high-value markets.
- GBL's broad specialty portfolio is well-aligned with this structural demand shift.
- Against high-cost import of ethanol our ethanol production for captive consumption is our strength.



Bio vs Fossil - The Gap Is Closing Fast

- Price parity with fossil fuels is within reach, making bio-based the economical choice.
- Strengthening competitiveness of bio-based alternatives.

A world in energy transition is paving the way for exactly what GBL creates - bio-based, reliable solutions.

Beyond E20

Energy Security

Geopolitical uncertainties and crude oil supply volatility reinforce the strategic role of domestically produced ethanol in enhancing India's energy security while reducing dependence on imported fossil fuels.

Beyond E20

Following the successful E20 rollout, policy discussions are expanding towards higher ethanol blends, flex-fuel vehicles and new transport fuel applications, supporting the next phase of ethanol demand.

Feedstock Diversification

India's ethanol ecosystem is increasingly adopting multiple feedstock pathways, including sugarcane and grains, creating a more resilient, scalable and year-round supply framework.

Our Competitive Advantage

Dual-feedstock Flexibility

200 KLPD grain-based distillery complements the existing sugar-based platform, enabling ability to process sugarcane and grain-based feedstocks providing flexibility to optimize operations across varying sugar seasons and market conditions.

Reliable Global Supply Partner


Global supply tightness is making GBL's Ethanol available as a feedstock to its bio-based production and supply reliability, a preferred source for export customers.

Q1 FY27 Highlights




(Rs. in Crs)


TOTAL REVENUE




EBITDA | EBITDA MARGIN




PAT & MARGIN



Q1 FY27 Revenue-Mix %



Q1 FY26 Revenue-Mix %




■ Sugar & Cogeneration
 ■ Bio-Based Chemicals
 ■ Ethanol
 ■ Unallocated


Q1 FY27 vs Q1 FY26 FINANCIAL PERFORMANCE

(Rs. in Crs)


REVENUE



EBITDA




EBITDA MARGIN %




Q1 FY27 vs Q1 FY26 FINANCIAL PERFORMANCE

(Rs. in Crs)


REVENUE



EBITDA



EBITDA MARGIN %



Consolidated Profit & Loss Statement – Q1 FY27

Particulars (in INR Crs)	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	FY26
Revenue from Operations	557.9	533.2	4.6%	564.1	1,987.9
Other Income	2.0	0.7		5.9	12.2
Total Income	559.9	534.0	4.9%	570.0	2,000.2
Cost of Materials Consumed	185.5	205.5		681.8	1,489.1
Purchase of Finished Goods	10.4	8.4		6.1	28.9
Changes in Inventories of Finished Goods and WIP	263.2	217.7		(341.6)	(91.4)
Gross Profit	100.9	102.4	(1.5%)	223.7	573.5
GP %	18.0%	19.2%		39.2%	28.7%
Employee Benefits Expense	33.0	32.2		36.7	135.2
Other Expenses	65.3	63.8		94.9	299.0
EBITDA*	2.6	6.5	(60.5%)	92.1	139.3
EBITDA %	0.5%	1.2%		16.2%	7.0%
Depreciation and Amortisation Expense	14.5	13.5		13.9	54.5
EBIT	(11.9)	(7.0)		78.2	84.8
Finance Costs	13.9	15.3		11.3	49.1
Profit before exceptional expense	(25.8)	(22.3)		66.9	35.7
Exceptional Expenses	0.0	0.0		(3.4) [#]	31.1 [#]
Profit/(Loss) before tax for the period	(25.8)	(22.3)		70.3	4.6
Tax Expense	(6.5)	(6.3)		17.4	1.0
Profit/(Loss) after Tax	(19.3)	(16.0)		52.9	3.5

*EBITDA includes Other Income [#]Exceptional items relate to additional harvesting charges for the 2023-24 sugar season and the impact of New Labour Codes

Strategy & Guidance





Soil Health

Restoring organic matter & microbiome health across GBL's farming network.



Farmer Empowerment

Co-creating prosperity with farmers through GBL programs.



Regenerative Agriculture

Supplementing & reducing dependence on fossil-based fertilizers.

"Everything we do begins with the sun, the soil, and the small farmer."

LEAD MOLECULE: MSP008-22 (FIRST-IN-CLASS)

About the Molecule

The lead anti-cancer molecule, **MSP008-22**, is a first-in-class, oral small molecule inhibitor currently being developed by Sathgen Therapeutics, a division of Godavari Biorefineries Ltd.

Target Indication

Because TNBC (Triple-Negative Breast Cancer) is a particularly difficult-to-treat subtype (accounting for approximately 15% of all breast cancer cases), Sathgen is focusing on developing novel therapies to address this high unmet need.


Current Development Status

The Clinical Study Report for the safety trials has been successfully submitted. We have filed the application to the CDSCO for the next step of trials (preliminary efficacy) for approval.

Milestones to Achieve

- **Q3 FY27:** Trial to start by Q3FY27 subject to Government approvals.
- **Q2 FY28:** Preliminary results of trials to be received.
- **Advanced Phase:** If positive results are achieved, marketing initiatives will commence.
- **Q2 2030 (Completion):** For full completion of trials, it is estimated to take 33 months, reaching final completion by Q2 2030.

BIO-BASED CHEMICALS REVENUE PERFORMANCE & PROJECTIONS





To mitigate climate risks, policy changes, market conditions, enhance supply chain resilience, and strengthen future margins, exploring increasing the corn/grain capacity to a dual and fungible 360 KLPD within the existing capacity 800 KLPD limit.

Current Status

Added dual-feedstock 200 KLPD corn/grain-based distillery in Q1FY27


Next Phase

Exploring optionality of 160 KLPD capacity.

Strategic Outcome

- a. Active participation in the ethanol blending program
- b. Leveraging favorable sugar market dynamics.

CAPACITY



Expanded our ethanol capacity from a 600 KLPD sugarcane-based ethanol by commissioning a 200 KLPD corn/grain facility, bringing the total capacity to 800KLPD.

To mitigate climate risks, enhance supply chain resilience, and strengthen future margins, exploring to increase the corn/grain capacity to a dual and fungible 360KLPD within the existing capacity 800 KLPD limit.

Growth with optionality

It helps to increase in

- Expanding the business
- Improving capacity utilization
- Creating an optionality of feedstock and its finished goods.

Bio-Butanol

Scaling High-Value Green Chemistry through Global Partnerships

- India is seeking to develop indigenous, scalable, and commercially viable technologies for the production of Bio-Butanol as next-generation diesel-blending fuels.
- Synthomer partnership expands GBL's bio-based monomer and specialty chemicals portfolio into global markets
- Looking for another prospective partner in the bio butanol market.
- Catalyxx collaboration strengthens technology readiness.

DME (Dimethyl Ether)

Turning Carbon Into a Strategic Clean Energy Opportunity

- GBL's DME project, in collaboration with ICT, is advancing pilot-scale validation for the conversion of CO₂ and hydrogen, with trials expected to conclude by Q4 FY27
- Opens a future-ready clean energy growth vertical aligned with decarbonization and energy transition trends
- Reinforces GBL's leadership in climate innovation, circular carbon utilization, and ESG-driven growth.

Turning Global Challenges into a Catalyst for Operational Excellence and Strategic Growth.





BIO INNOVATIONS APAC 2026, SINGAPORE

Dr. Sangeeta Srivastava represented India and spoke on “From the Soil to Valuable Bio-Chemicals and Bio-Products”.



5TH INDIA GREEN ENERGY AWARDS 2025

Winner – Bioenergy Producer New Delhi



US TRADE DELEGATION

Represented GBL in an Indian trade delegation to the United States, engaging with agricultural leaders and policymakers across key states.



RESPONSIBLE CARE CERTIFICATION

Renewal confirmed at ICC Lognext 2026, reaffirming GBL's commitment to safe and responsible operations.



Godavari Biorefineries Ltd
CIN: L67120MH1956PLC009707
Name – Mr. Ashish Sinha
Title – DGM- IR & Finance
Email – investorrelations@somaiya.com



Ms. Prachi Ambre
Prachi.ambre@in.mpms.mufg.com

Mr. Irfan Raeen
irfan.raeen@in.mpms.mufg.com

Meeting Request

Link

Website: <https://in.mpms.mufg.com/>

